Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B
L Fuino, P Bali, S Wittmann, S Donapaty, F Guo… - Molecular cancer …, 2003 - AACR
Histone deacetylase inhibitors induce hyperacetylation of the amino-terminal lysine residues
of the core nucleosomal histones, which results in chromatin remodeling and altered gene …
of the core nucleosomal histones, which results in chromatin remodeling and altered gene …
Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2
P Bali, M Pranpat, R Swaby, W Fiskus… - Clinical cancer …, 2005 - AACR
Purpose: We determined the effects of suberoylanilide hydroxamic acid (SAHA), a histone
deacetylase inhibitor, on hsp90 and its client proteins Her-2, AKT, and c-Raf, as well as …
deacetylase inhibitor, on hsp90 and its client proteins Her-2, AKT, and c-Raf, as well as …
Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1
CY Gui, L Ngo, WS Xu, VM Richon… - Proceedings of the …, 2004 - National Acad Sciences
Histone deacetylase (HDAC) inhibitors (HDACi) cause cancer cell growth arrest and/or
apoptosis in vivo and in vitro. The HDACi suberoylanilide hydroxamic acid (SAHA) is in …
apoptosis in vivo and in vitro. The HDACi suberoylanilide hydroxamic acid (SAHA) is in …
A novel HSP90 inhibitor targeting the C-terminal domain attenuates trastuzumab resistance in HER2-positive breast cancer
Trastuzumab resistance in HER2-positive breast cancer is associated with a poorer
prognosis. HSP90 is thought to play a major role in such resistance, but N-terminal inhibitors …
prognosis. HSP90 is thought to play a major role in such resistance, but N-terminal inhibitors …
The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen …
RR Rosato, JA Almenara, S Grant - Cancer research, 2003 - AACR
Abstract Effects of the histone deacetylase (HDAC) inhibitor MS-275 have been examined in
human leukemia and lymphoma cells (U937, HL-60, K562, and Jurkat) as well as in primary …
human leukemia and lymphoma cells (U937, HL-60, K562, and Jurkat) as well as in primary …
A new synthetic histone deacetylase inhibitor, MHY2256, induces apoptosis and autophagy cell death in endometrial cancer cells via p53 acetylation
U De, JY Son, R Sachan, YJ Park, D Kang… - International Journal of …, 2018 - mdpi.com
We previously discovered a novel sirtuin (SIRT) inhibitor, MHY2256, that exerts anticancer
activity through p53 acetylation in MCF-7 human breast cancer cells. We investigated the …
activity through p53 acetylation in MCF-7 human breast cancer cells. We investigated the …
Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity
MV Blagosklonny, R Robey, DL Sackett, L Du… - Molecular cancer …, 2002 - AACR
By preventing deacetylation of histones, histone deacetylase inhibitors (HDIs)
transcriptionally induce p21. Here we show that the HDIs sodium butyrate (Bu), trichostatin A …
transcriptionally induce p21. Here we show that the HDIs sodium butyrate (Bu), trichostatin A …
Inhibition of HSP90 with AUY922 induces synergy in HER2-amplified trastuzumab-resistant breast and gastric cancer
ZA Wainberg, A Anghel, AM Rogers, AJ Desai… - Molecular cancer …, 2013 - AACR
HSP90 enables the activation of many client proteins of which the most clinically validated is
HER2. NVP-AUY922, a potent HSP90 inhibitor, is currently in phase II clinical trials. To …
HER2. NVP-AUY922, a potent HSP90 inhibitor, is currently in phase II clinical trials. To …
Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228
X Yu, ZS Guo, MG Marcu, L Neckers… - Journal of the …, 2002 - academic.oup.com
Abstract Background: Histone deacetylases (HDACs) modulate chromatin structure by
regulating acetylation of core histone proteins. HDAC inhibitors, such as depsipeptide …
regulating acetylation of core histone proteins. HDAC inhibitors, such as depsipeptide …
Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation
VM Richon, TW Sandhoff… - Proceedings of the …, 2000 - National Acad Sciences
Histone deacetylases (HDACs) catalyze the removal of acetyl groups on the amino-terminal
lysine residues of core nucleosomal histones. This activity is associated generally with …
lysine residues of core nucleosomal histones. This activity is associated generally with …